Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25197751 | 0.88 | CHRNB2 (0.53) | CHRNB2CHRNA4LRRK2ACACBHRH4 | |
| SCHEMBL20000567 | 0.87 | CHRNB2 (0.47) | CHRNB2CHRNA4LRRK2ACACBGPR119 | |
| SCHEMBL25193011 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNA4LRRK2ACACB | |
| SCHEMBL25416857 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA4LRRK2FLT3 | |
| SCHEMBL11978475 | 0.80 | GPR119 (0.52) | CHRNB2CHRNA4LRRK2ACACBGPR119 | |
| SCHEMBL788430 | 0.79 | SIGMAR1 (0.56) | — | |
| SCHEMBL31401416 | 0.77 | CHRNB2 (0.88) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2617751 | 0.77 | CHRNB2 (0.88) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25190945 | 0.77 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL3104363 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4ACACBFLT3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| EP-2167490-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Korea Research Institute Of Chemical Technology (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153325-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CYP51A1, ERG28, CYP3A7 | CHRNB2 4863/4885CHRNA4 4851/4885LRRK2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.